2030 Clinical Trials Data 
Cannabis Law Report
JUNE 7, 2021
IGC”) (NYSE American: IGC) announces today that it has completed Cohort 2 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (“THC”)-based investigational new drug, IGC-AD1, intended to alleviate the symptoms of individuals suffering from Alzheimer’s disease. This Phase 1 trial is currently testing IGC-AD1 for safety.
Cannabis Law Report
DECEMBER 17, 2021
Deletion Syndrome – Global Market Insights, Epidemiology and Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering. deletion syndrome in the 7MM covering United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2018 to 2030. Country-Wise Epidemiology.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
AUGUST 10, 2021
This acquisition is focused on becoming the first and only company solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. from 2020 to 2030 and generate revenue of $151.7 billion in 2030. The purchase price of CDN$2,500,000.00 2014; 7: 115-124.
Cannabis Law Report
JUNE 30, 2021
According to the Lancet Commission, mental health disorders are on the rise in every country worldwide, and the resulting lost productivity will cost the global economy $16 trillion by 2030. Building the Data Backend. MedXtractor Corp.’s Mental Health Challenges. Psychedelics could offer a better alternative for many patients.
Cannabis Law Report
DECEMBER 21, 2021
The rapid increase in the volume of enterprise data and growing automation of business processes across several end-use industries such as retail, manufacturing, healthcare, and transportation are expected to drive the demand for business software and services over the forecast period. billion by 2030, growing at a CAGR of 8.4%
Expert insights. Personalized for you.
105 
Let's personalize your content